175 related articles for article (PubMed ID: 21386628)
21. Translational challenges from the 2014 Gastrointestinal Cancers Symposium: toward a true tailored therapy through effective research.
Aprile G; Giuliani F; Cordio S; Sartore-Bianchi A; Bencardino K; Ongaro E; Martines C; Giampieri R; Bordonaro R; Siena S; Cascinu S; Scartozzi M
Future Oncol; 2014 May; 10(7):1125-8. PubMed ID: 24947252
[TBL] [Abstract][Full Text] [Related]
22. Translational research. New findings and potential future applications in pancreatic adenocarcinoma.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2012 Mar; 13(2):177-9. PubMed ID: 22406595
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant strategies for resectable pancreatic cancer: have we made progress?
Russo S; Jain AK; Saif MW
JOP; 2012 Mar; 13(2):139-42. PubMed ID: 22406585
[TBL] [Abstract][Full Text] [Related]
24. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.
Rachagani S; Macha MA; Heimann N; Seshacharyulu P; Haridas D; Chugh S; Batra SK
Adv Drug Deliv Rev; 2015 Jan; 81():16-33. PubMed ID: 25453266
[TBL] [Abstract][Full Text] [Related]
25. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion.
Stoffel EM; McKernin SE; Brand R; Canto M; Goggins M; Moravek C; Nagarajan A; Petersen GM; Simeone DM; Yurgelun M; Khorana AA
J Clin Oncol; 2019 Jan; 37(2):153-164. PubMed ID: 30457921
[TBL] [Abstract][Full Text] [Related]
26. Current and future biomarkers for pancreatic adenocarcinoma.
Loosen SH; Neumann UP; Trautwein C; Roderburg C; Luedde T
Tumour Biol; 2017 Jun; 39(6):1010428317692231. PubMed ID: 28618958
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers in pancreatic neuroendocrine tumors.
Theochari MS; Syrigos KN; Saif MW
JOP; 2014 Mar; 15(2):138-9. PubMed ID: 24618438
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic tools in pancreatic cancer.
Hoimes CJ; Strimpakos AS; Saif MW
JOP; 2009 Mar; 10(2):118-22. PubMed ID: 19287103
[TBL] [Abstract][Full Text] [Related]
29. Resectable pancreatic cancer: is surgery the best first step?
Russo S; Chabot J; Saif MW
JOP; 2012 Mar; 13(2):151-4. PubMed ID: 22406588
[TBL] [Abstract][Full Text] [Related]
30. BRCA and pancreatic cancer: selection of chemotherapy.
Kim R; Byer J; Saif MW
JOP; 2012 Mar; 13(2):180-1. PubMed ID: 22406596
[TBL] [Abstract][Full Text] [Related]
31. Pancreatic cancer: the role of molecular markers in diagnosis and management.
Lowery MA; O'Reilly EM
Clin Adv Hematol Oncol; 2011 Dec; 9(12):900-8. PubMed ID: 22252658
[TBL] [Abstract][Full Text] [Related]
32. Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with Pancreatic Adenocarcinoma.
Costache MI; Iordache S; Costache CA; Dragos E; Dragos A; Saftoiu A
J Gastrointestin Liver Dis; 2017 Mar; 26(1):51-57. PubMed ID: 28338114
[TBL] [Abstract][Full Text] [Related]
33. Genetic predisposition to pancreatic cancer.
Ghiorzo P
World J Gastroenterol; 2014 Aug; 20(31):10778-89. PubMed ID: 25152581
[TBL] [Abstract][Full Text] [Related]
34. An introduction to pancreatic adenocarcinoma genetics, pathology and therapy.
Kern SE; Hruban RH; Hidalgo M; Yeo CJ
Cancer Biol Ther; 2002; 1(6):607-13. PubMed ID: 12642681
[TBL] [Abstract][Full Text] [Related]
35. MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma.
Vychytilova-Faltejskova P; Kiss I; Klusova S; Hlavsa J; Prochazka V; Kala Z; Mazanec J; Hausnerova J; Kren L; Hermanova M; Lenz J; Karasek P; Vyzula R; Slaby O
Diagn Pathol; 2015 Apr; 10():38. PubMed ID: 25908274
[TBL] [Abstract][Full Text] [Related]
36. Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer.
Buti S; Ciccarese C; Iacovelli R; Bersanelli M; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R; Tortora G; Massari F
Future Oncol; 2016 Sep; 12(17):1967-70. PubMed ID: 27312426
[TBL] [Abstract][Full Text] [Related]
37. Locally advanced pancreatic adenocarcinoma: update and progress.
Ng J; Zhang C; Gidea-Addeo D; Saif MW
JOP; 2012 Mar; 13(2):155-8. PubMed ID: 22406589
[TBL] [Abstract][Full Text] [Related]
38. Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
Richter J; Saif MW
JOP; 2010 Mar; 11(2):139-43. PubMed ID: 20208322
[TBL] [Abstract][Full Text] [Related]
39. A review on the role of microRNA in biology, diagnosis, and treatment of pancreatic adenocarcinoma.
Papaconstantinou IG; Lykoudis PM; Gazouli M; Manta A; Polymeneas G; Voros D
Pancreas; 2012 Jul; 41(5):671-7. PubMed ID: 22695087
[TBL] [Abstract][Full Text] [Related]
40. Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent.
Crnogorac-Jurcevic T; Missiaglia E; Blaveri E; Gangeswaran R; Jones M; Terris B; Costello E; Neoptolemos JP; Lemoine NR
J Pathol; 2003 Sep; 201(1):63-74. PubMed ID: 12950018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
